In vivo CYP2E1 phenotyping as a new potential biomarker of occupational and experimental exposure to benzene
Assessing CYP2E1 phenotype in vivo may be important to predict individual susceptibility to those chemicals, including benzene, which are metabolically activated by this isoenzyme. Chlorzoxazone (CHZ), a specific CYP2E1 substrate, is readily hydroxylated to 6-OH-chlorzoxazone (6-OH-CHZ) by liver CYP...
Gespeichert in:
Veröffentlicht in: | Toxicology letters 2010-01, Vol.192 (1), p.29-33 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 33 |
---|---|
container_issue | 1 |
container_start_page | 29 |
container_title | Toxicology letters |
container_volume | 192 |
creator | Piccoli, P. Carrieri, M. Padovano, L. Di Mare, M. Bartolucci, G.B. Fracasso, M.E. Lepera, J.S. Manno, M. |
description | Assessing CYP2E1 phenotype
in vivo may be important to predict individual susceptibility to those chemicals, including benzene, which are metabolically activated by this isoenzyme. Chlorzoxazone (CHZ), a specific CYP2E1 substrate, is readily hydroxylated to 6-OH-chlorzoxazone (6-OH-CHZ) by liver CYP2E1 and the metabolic ratio 6-OH-CHZ/CHZ in serum (MR) is a specific and sensitive biomarker of CYP2E1 activity
in vivo in humans. We used this MR as a potential biomarker of effect in benzene-treated rats and, also, in humans occupationally exposed to low levels of benzene. Male Sprague-Dawley rats (375–400
g b.w.) were treated
i.p. for 3 days with either a 0.5
ml solution of benzene (5
mmol/kg b.w.) in corn oil, or 0.5
ml corn oil alone. Twenty-four hours after the last injection, a polyethylene glycol (PEG) solution of CHZ (20
mg/kg b.w.) was injected
i.p. in both treated and control animals. After 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, and 240
min from injection, 0.2
ml blood was taken from the tip tail and stored at −20
°C until analysis. A modified reverse phase HPLC method using a 5
μm Ultrasphere C18 column equipped with a direct-connection ODS guard column, was used to measure CHZ and its metabolite 6-OH-CHZ in serum. No statistically significant difference in the MR was observed, at any sampling time, between benzene-treated and control rats. The concentration-versus-time area under the curve (AUC), however, was lower (
p
<
0.05, Mann–Whitney test), whereas the systemic clearance was higher (
p
<
0.05) in treated than in control rats. Eleven petrochemical workers occupationally exposed to low levels of airborne benzene (mean
±
SD, 25.0
±
24.4
μg/m
3) and 13 non-exposed controls from the same factory (mean
±
SD, 6.7
±
4.0
μg/m
3) signed an informed consent form and were administered 500
mg CHZ
p.o. Two hours later a venous blood sample was taken for CHZ and 6-OH-CHZ measurements. Despite exposed subjects showed significantly higher levels of
t,t-MA and S-PMA, two biomarkers of exposure to benzene, than non-exposed workers, no difference in the MR mean values
±
SD was found between exposed (0.59
±
0.29) and non-exposed (0.57
±
0.23) subjects. So, benzene was found to modify CHZ disposition, but not CYP2E1 phenotype in benzene-treated rats, nor in workers exposed to benzene, probably due to the levels of exposure being too low. |
doi_str_mv | 10.1016/j.toxlet.2009.10.023 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_744613006</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378427409014787</els_id><sourcerecordid>733618167</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-248db3e0822132ac335507fccce697fe1a07ba5757afa54408c10970e04557ec3</originalsourceid><addsrcrecordid>eNqFkU9v1DAQxSMEotvCN0DIFwSXLOP4X3JBqlalVKoEBzhwshzvBLxk7WA7S8unx9Gu4FZOo3n-zYz1XlW9oLCmQOXb3TqHuxHzugHoirSGhj2qVrRVXc2o7B5XK2CqrXmj-Fl1ntIOACSX4ml1RrsOQFC-qsYbTw7uEMjm66fmipLpO_qQ7yfnvxGTiCEef5EpZPTZmZH0LuxN_IGRhIEEa-fJZBd8eTF-S_Buwuj2hS1CaUKaI5IcSI_-N3p8Vj0ZzJjw-aleVF_eX33efKhvP17fbC5va8uFzHXD223PENqmoawxljEhQA3WWpSdGpAaUL0RSigzGME5tJZCpwCBC6HQsovq9XHvFMPPGVPWe5csjqPxGOakFeeSsuLG_0nGJG2pVIV88yBZGMpBglqW8iNqY0gp4qCn4oqJ95qCXrLTO33MTi_ZLWrJroy9PF2Y-z1u_w2dwirAqxNgkjXjEI23Lv3lmqY40YmFe3fksHh8cBh1sg69xa2LaLPeBvfwT_4AwPq5Fg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1671406076</pqid></control><display><type>article</type><title>In vivo CYP2E1 phenotyping as a new potential biomarker of occupational and experimental exposure to benzene</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Piccoli, P. ; Carrieri, M. ; Padovano, L. ; Di Mare, M. ; Bartolucci, G.B. ; Fracasso, M.E. ; Lepera, J.S. ; Manno, M.</creator><creatorcontrib>Piccoli, P. ; Carrieri, M. ; Padovano, L. ; Di Mare, M. ; Bartolucci, G.B. ; Fracasso, M.E. ; Lepera, J.S. ; Manno, M.</creatorcontrib><description>Assessing CYP2E1 phenotype
in vivo may be important to predict individual susceptibility to those chemicals, including benzene, which are metabolically activated by this isoenzyme. Chlorzoxazone (CHZ), a specific CYP2E1 substrate, is readily hydroxylated to 6-OH-chlorzoxazone (6-OH-CHZ) by liver CYP2E1 and the metabolic ratio 6-OH-CHZ/CHZ in serum (MR) is a specific and sensitive biomarker of CYP2E1 activity
in vivo in humans. We used this MR as a potential biomarker of effect in benzene-treated rats and, also, in humans occupationally exposed to low levels of benzene. Male Sprague-Dawley rats (375–400
g b.w.) were treated
i.p. for 3 days with either a 0.5
ml solution of benzene (5
mmol/kg b.w.) in corn oil, or 0.5
ml corn oil alone. Twenty-four hours after the last injection, a polyethylene glycol (PEG) solution of CHZ (20
mg/kg b.w.) was injected
i.p. in both treated and control animals. After 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, and 240
min from injection, 0.2
ml blood was taken from the tip tail and stored at −20
°C until analysis. A modified reverse phase HPLC method using a 5
μm Ultrasphere C18 column equipped with a direct-connection ODS guard column, was used to measure CHZ and its metabolite 6-OH-CHZ in serum. No statistically significant difference in the MR was observed, at any sampling time, between benzene-treated and control rats. The concentration-versus-time area under the curve (AUC), however, was lower (
p
<
0.05, Mann–Whitney test), whereas the systemic clearance was higher (
p
<
0.05) in treated than in control rats. Eleven petrochemical workers occupationally exposed to low levels of airborne benzene (mean
±
SD, 25.0
±
24.4
μg/m
3) and 13 non-exposed controls from the same factory (mean
±
SD, 6.7
±
4.0
μg/m
3) signed an informed consent form and were administered 500
mg CHZ
p.o. Two hours later a venous blood sample was taken for CHZ and 6-OH-CHZ measurements. Despite exposed subjects showed significantly higher levels of
t,t-MA and S-PMA, two biomarkers of exposure to benzene, than non-exposed workers, no difference in the MR mean values
±
SD was found between exposed (0.59
±
0.29) and non-exposed (0.57
±
0.23) subjects. So, benzene was found to modify CHZ disposition, but not CYP2E1 phenotype in benzene-treated rats, nor in workers exposed to benzene, probably due to the levels of exposure being too low.</description><identifier>ISSN: 0378-4274</identifier><identifier>EISSN: 1879-3169</identifier><identifier>DOI: 10.1016/j.toxlet.2009.10.023</identifier><identifier>PMID: 19900514</identifier><identifier>CODEN: TOLED5</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>6-OH-chlorzoxazone ; Acetylcysteine - analogs & derivatives ; Acetylcysteine - urine ; Animals ; Area Under Curve ; Benzene ; Benzene - pharmacokinetics ; Benzene - toxicity ; Biocompatibility ; Biological and medical sciences ; Biomarkers - blood ; Biomarkers - metabolism ; Biomedical materials ; Chlorzoxazone ; Chlorzoxazone - analogs & derivatives ; Chlorzoxazone - blood ; Chlorzoxazone - pharmacokinetics ; Chromatography, High Pressure Liquid ; CYP2E1 ; Cytochrome P-450 CYP2E1 - metabolism ; Exposure ; Humans ; In vivo testing ; In vivo tests ; Male ; Medical sciences ; Metabolic phenotype ; Occupational Exposure - analysis ; Phenotype ; Random Allocation ; Rats ; Rats, Sprague-Dawley ; Sorbic Acid - analogs & derivatives ; Sorbic Acid - analysis ; Statistics, Nonparametric ; Surgical implants ; Toxicology</subject><ispartof>Toxicology letters, 2010-01, Vol.192 (1), p.29-33</ispartof><rights>2009 Elsevier Ireland Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright 2009 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-248db3e0822132ac335507fccce697fe1a07ba5757afa54408c10970e04557ec3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0378427409014787$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,776,780,785,786,3537,23909,23910,25118,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22408954$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19900514$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Piccoli, P.</creatorcontrib><creatorcontrib>Carrieri, M.</creatorcontrib><creatorcontrib>Padovano, L.</creatorcontrib><creatorcontrib>Di Mare, M.</creatorcontrib><creatorcontrib>Bartolucci, G.B.</creatorcontrib><creatorcontrib>Fracasso, M.E.</creatorcontrib><creatorcontrib>Lepera, J.S.</creatorcontrib><creatorcontrib>Manno, M.</creatorcontrib><title>In vivo CYP2E1 phenotyping as a new potential biomarker of occupational and experimental exposure to benzene</title><title>Toxicology letters</title><addtitle>Toxicol Lett</addtitle><description>Assessing CYP2E1 phenotype
in vivo may be important to predict individual susceptibility to those chemicals, including benzene, which are metabolically activated by this isoenzyme. Chlorzoxazone (CHZ), a specific CYP2E1 substrate, is readily hydroxylated to 6-OH-chlorzoxazone (6-OH-CHZ) by liver CYP2E1 and the metabolic ratio 6-OH-CHZ/CHZ in serum (MR) is a specific and sensitive biomarker of CYP2E1 activity
in vivo in humans. We used this MR as a potential biomarker of effect in benzene-treated rats and, also, in humans occupationally exposed to low levels of benzene. Male Sprague-Dawley rats (375–400
g b.w.) were treated
i.p. for 3 days with either a 0.5
ml solution of benzene (5
mmol/kg b.w.) in corn oil, or 0.5
ml corn oil alone. Twenty-four hours after the last injection, a polyethylene glycol (PEG) solution of CHZ (20
mg/kg b.w.) was injected
i.p. in both treated and control animals. After 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, and 240
min from injection, 0.2
ml blood was taken from the tip tail and stored at −20
°C until analysis. A modified reverse phase HPLC method using a 5
μm Ultrasphere C18 column equipped with a direct-connection ODS guard column, was used to measure CHZ and its metabolite 6-OH-CHZ in serum. No statistically significant difference in the MR was observed, at any sampling time, between benzene-treated and control rats. The concentration-versus-time area under the curve (AUC), however, was lower (
p
<
0.05, Mann–Whitney test), whereas the systemic clearance was higher (
p
<
0.05) in treated than in control rats. Eleven petrochemical workers occupationally exposed to low levels of airborne benzene (mean
±
SD, 25.0
±
24.4
μg/m
3) and 13 non-exposed controls from the same factory (mean
±
SD, 6.7
±
4.0
μg/m
3) signed an informed consent form and were administered 500
mg CHZ
p.o. Two hours later a venous blood sample was taken for CHZ and 6-OH-CHZ measurements. Despite exposed subjects showed significantly higher levels of
t,t-MA and S-PMA, two biomarkers of exposure to benzene, than non-exposed workers, no difference in the MR mean values
±
SD was found between exposed (0.59
±
0.29) and non-exposed (0.57
±
0.23) subjects. So, benzene was found to modify CHZ disposition, but not CYP2E1 phenotype in benzene-treated rats, nor in workers exposed to benzene, probably due to the levels of exposure being too low.</description><subject>6-OH-chlorzoxazone</subject><subject>Acetylcysteine - analogs & derivatives</subject><subject>Acetylcysteine - urine</subject><subject>Animals</subject><subject>Area Under Curve</subject><subject>Benzene</subject><subject>Benzene - pharmacokinetics</subject><subject>Benzene - toxicity</subject><subject>Biocompatibility</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Biomarkers - metabolism</subject><subject>Biomedical materials</subject><subject>Chlorzoxazone</subject><subject>Chlorzoxazone - analogs & derivatives</subject><subject>Chlorzoxazone - blood</subject><subject>Chlorzoxazone - pharmacokinetics</subject><subject>Chromatography, High Pressure Liquid</subject><subject>CYP2E1</subject><subject>Cytochrome P-450 CYP2E1 - metabolism</subject><subject>Exposure</subject><subject>Humans</subject><subject>In vivo testing</subject><subject>In vivo tests</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metabolic phenotype</subject><subject>Occupational Exposure - analysis</subject><subject>Phenotype</subject><subject>Random Allocation</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Sorbic Acid - analogs & derivatives</subject><subject>Sorbic Acid - analysis</subject><subject>Statistics, Nonparametric</subject><subject>Surgical implants</subject><subject>Toxicology</subject><issn>0378-4274</issn><issn>1879-3169</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9v1DAQxSMEotvCN0DIFwSXLOP4X3JBqlalVKoEBzhwshzvBLxk7WA7S8unx9Gu4FZOo3n-zYz1XlW9oLCmQOXb3TqHuxHzugHoirSGhj2qVrRVXc2o7B5XK2CqrXmj-Fl1ntIOACSX4ml1RrsOQFC-qsYbTw7uEMjm66fmipLpO_qQ7yfnvxGTiCEef5EpZPTZmZH0LuxN_IGRhIEEa-fJZBd8eTF-S_Buwuj2hS1CaUKaI5IcSI_-N3p8Vj0ZzJjw-aleVF_eX33efKhvP17fbC5va8uFzHXD223PENqmoawxljEhQA3WWpSdGpAaUL0RSigzGME5tJZCpwCBC6HQsovq9XHvFMPPGVPWe5csjqPxGOakFeeSsuLG_0nGJG2pVIV88yBZGMpBglqW8iNqY0gp4qCn4oqJ95qCXrLTO33MTi_ZLWrJroy9PF2Y-z1u_w2dwirAqxNgkjXjEI23Lv3lmqY40YmFe3fksHh8cBh1sg69xa2LaLPeBvfwT_4AwPq5Fg</recordid><startdate>20100115</startdate><enddate>20100115</enddate><creator>Piccoli, P.</creator><creator>Carrieri, M.</creator><creator>Padovano, L.</creator><creator>Di Mare, M.</creator><creator>Bartolucci, G.B.</creator><creator>Fracasso, M.E.</creator><creator>Lepera, J.S.</creator><creator>Manno, M.</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FD</scope><scope>FR3</scope><scope>KR7</scope><scope>7X8</scope><scope>7ST</scope><scope>7T2</scope><scope>7U2</scope><scope>7U7</scope><scope>C1K</scope><scope>SOI</scope></search><sort><creationdate>20100115</creationdate><title>In vivo CYP2E1 phenotyping as a new potential biomarker of occupational and experimental exposure to benzene</title><author>Piccoli, P. ; Carrieri, M. ; Padovano, L. ; Di Mare, M. ; Bartolucci, G.B. ; Fracasso, M.E. ; Lepera, J.S. ; Manno, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-248db3e0822132ac335507fccce697fe1a07ba5757afa54408c10970e04557ec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>6-OH-chlorzoxazone</topic><topic>Acetylcysteine - analogs & derivatives</topic><topic>Acetylcysteine - urine</topic><topic>Animals</topic><topic>Area Under Curve</topic><topic>Benzene</topic><topic>Benzene - pharmacokinetics</topic><topic>Benzene - toxicity</topic><topic>Biocompatibility</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Biomarkers - metabolism</topic><topic>Biomedical materials</topic><topic>Chlorzoxazone</topic><topic>Chlorzoxazone - analogs & derivatives</topic><topic>Chlorzoxazone - blood</topic><topic>Chlorzoxazone - pharmacokinetics</topic><topic>Chromatography, High Pressure Liquid</topic><topic>CYP2E1</topic><topic>Cytochrome P-450 CYP2E1 - metabolism</topic><topic>Exposure</topic><topic>Humans</topic><topic>In vivo testing</topic><topic>In vivo tests</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metabolic phenotype</topic><topic>Occupational Exposure - analysis</topic><topic>Phenotype</topic><topic>Random Allocation</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Sorbic Acid - analogs & derivatives</topic><topic>Sorbic Acid - analysis</topic><topic>Statistics, Nonparametric</topic><topic>Surgical implants</topic><topic>Toxicology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Piccoli, P.</creatorcontrib><creatorcontrib>Carrieri, M.</creatorcontrib><creatorcontrib>Padovano, L.</creatorcontrib><creatorcontrib>Di Mare, M.</creatorcontrib><creatorcontrib>Bartolucci, G.B.</creatorcontrib><creatorcontrib>Fracasso, M.E.</creatorcontrib><creatorcontrib>Lepera, J.S.</creatorcontrib><creatorcontrib>Manno, M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Civil Engineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Environment Abstracts</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Safety Science and Risk</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Environment Abstracts</collection><jtitle>Toxicology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Piccoli, P.</au><au>Carrieri, M.</au><au>Padovano, L.</au><au>Di Mare, M.</au><au>Bartolucci, G.B.</au><au>Fracasso, M.E.</au><au>Lepera, J.S.</au><au>Manno, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vivo CYP2E1 phenotyping as a new potential biomarker of occupational and experimental exposure to benzene</atitle><jtitle>Toxicology letters</jtitle><addtitle>Toxicol Lett</addtitle><date>2010-01-15</date><risdate>2010</risdate><volume>192</volume><issue>1</issue><spage>29</spage><epage>33</epage><pages>29-33</pages><issn>0378-4274</issn><eissn>1879-3169</eissn><coden>TOLED5</coden><abstract>Assessing CYP2E1 phenotype
in vivo may be important to predict individual susceptibility to those chemicals, including benzene, which are metabolically activated by this isoenzyme. Chlorzoxazone (CHZ), a specific CYP2E1 substrate, is readily hydroxylated to 6-OH-chlorzoxazone (6-OH-CHZ) by liver CYP2E1 and the metabolic ratio 6-OH-CHZ/CHZ in serum (MR) is a specific and sensitive biomarker of CYP2E1 activity
in vivo in humans. We used this MR as a potential biomarker of effect in benzene-treated rats and, also, in humans occupationally exposed to low levels of benzene. Male Sprague-Dawley rats (375–400
g b.w.) were treated
i.p. for 3 days with either a 0.5
ml solution of benzene (5
mmol/kg b.w.) in corn oil, or 0.5
ml corn oil alone. Twenty-four hours after the last injection, a polyethylene glycol (PEG) solution of CHZ (20
mg/kg b.w.) was injected
i.p. in both treated and control animals. After 2, 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, and 240
min from injection, 0.2
ml blood was taken from the tip tail and stored at −20
°C until analysis. A modified reverse phase HPLC method using a 5
μm Ultrasphere C18 column equipped with a direct-connection ODS guard column, was used to measure CHZ and its metabolite 6-OH-CHZ in serum. No statistically significant difference in the MR was observed, at any sampling time, between benzene-treated and control rats. The concentration-versus-time area under the curve (AUC), however, was lower (
p
<
0.05, Mann–Whitney test), whereas the systemic clearance was higher (
p
<
0.05) in treated than in control rats. Eleven petrochemical workers occupationally exposed to low levels of airborne benzene (mean
±
SD, 25.0
±
24.4
μg/m
3) and 13 non-exposed controls from the same factory (mean
±
SD, 6.7
±
4.0
μg/m
3) signed an informed consent form and were administered 500
mg CHZ
p.o. Two hours later a venous blood sample was taken for CHZ and 6-OH-CHZ measurements. Despite exposed subjects showed significantly higher levels of
t,t-MA and S-PMA, two biomarkers of exposure to benzene, than non-exposed workers, no difference in the MR mean values
±
SD was found between exposed (0.59
±
0.29) and non-exposed (0.57
±
0.23) subjects. So, benzene was found to modify CHZ disposition, but not CYP2E1 phenotype in benzene-treated rats, nor in workers exposed to benzene, probably due to the levels of exposure being too low.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>19900514</pmid><doi>10.1016/j.toxlet.2009.10.023</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0378-4274 |
ispartof | Toxicology letters, 2010-01, Vol.192 (1), p.29-33 |
issn | 0378-4274 1879-3169 |
language | eng |
recordid | cdi_proquest_miscellaneous_744613006 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | 6-OH-chlorzoxazone Acetylcysteine - analogs & derivatives Acetylcysteine - urine Animals Area Under Curve Benzene Benzene - pharmacokinetics Benzene - toxicity Biocompatibility Biological and medical sciences Biomarkers - blood Biomarkers - metabolism Biomedical materials Chlorzoxazone Chlorzoxazone - analogs & derivatives Chlorzoxazone - blood Chlorzoxazone - pharmacokinetics Chromatography, High Pressure Liquid CYP2E1 Cytochrome P-450 CYP2E1 - metabolism Exposure Humans In vivo testing In vivo tests Male Medical sciences Metabolic phenotype Occupational Exposure - analysis Phenotype Random Allocation Rats Rats, Sprague-Dawley Sorbic Acid - analogs & derivatives Sorbic Acid - analysis Statistics, Nonparametric Surgical implants Toxicology |
title | In vivo CYP2E1 phenotyping as a new potential biomarker of occupational and experimental exposure to benzene |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T12%3A00%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vivo%20CYP2E1%20phenotyping%20as%20a%20new%20potential%20biomarker%20of%20occupational%20and%20experimental%20exposure%20to%20benzene&rft.jtitle=Toxicology%20letters&rft.au=Piccoli,%20P.&rft.date=2010-01-15&rft.volume=192&rft.issue=1&rft.spage=29&rft.epage=33&rft.pages=29-33&rft.issn=0378-4274&rft.eissn=1879-3169&rft.coden=TOLED5&rft_id=info:doi/10.1016/j.toxlet.2009.10.023&rft_dat=%3Cproquest_cross%3E733618167%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1671406076&rft_id=info:pmid/19900514&rft_els_id=S0378427409014787&rfr_iscdi=true |